Factive gemifloxacin mesylate regulatory update

FDA's Anti-Infective Drugs Advisory Committee will meet on Sept. 12 to review an sNDA for a 5-day regimen of Factive gemifloxacin mesylate to treat acute bacterial sinusitis (ABS). FDA refused to file...